Cargando…

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML

KMT2A-rearranged acute myeloid leukemia (KMT2Ar-AML) is an aggressive subtype of AML with poor response and prognosis. KMT2Ar-AML has been demonstrated to be sensitive to BCL2 inhibitor venetoclax (VEN), but these patients are unable to benefit from current VEN-based regimen (VEN plus azacitidine or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Qing, Zhou, Yutong, Qian, Yu, Qian, Jiejing, Zhang, Yi, Wang, Jinghan, Zhu, Yanan, Zhou, Yile, Wei, Juying, Yang, Chunmei, Sun, Jie, Yu, Wenjuan, Jin, Jie, Zhang, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696732/ http://dx.doi.org/10.1186/s40364-023-00547-9

Ejemplares similares

Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets
por: Lin, Wenchu, et al.
Publicado: (2016)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes
por: Sparbier, Christina E., et al.
Publicado: (2023)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
por: Khabusheva, Elmira, et al.
Publicado: (2023)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023)

The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML
por: Rasouli, Milad, et al.
Publicado: (2023)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2021)

AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition
por: Zhang, Mingming, et al.
Publicado: (2016)

Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism
por: Chou, Chih-Wei, et al.
Publicado: (2020)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

P410: COMBINING MENIN AND MEK INHIBITION TO TREAT CHILDREN WITH POOR PROGNOSTIC KMT2A-R RAS-MUTANT ACUTE LEUKEMIA
por: Scheidegger, Nastassja, et al.
Publicado: (2023)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
por: Tregnago, Claudia, et al.
Publicado: (2022)

Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
por: Ye, Jing, et al.
Publicado: (2019)

Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
por: Zhang, Lei-Si, et al.
Publicado: (2022)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

KMT2A-MLLT3 AML Masquerading as JMML may Disguise Fatal Leukemia
por: Saad, Ashraf Abdullah, et al.
Publicado: (2019)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

The role of menin in bone pathology
por: Gorbacheva, Anna, et al.
Publicado: (2022)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
por: Liu, Yifan, et al.
Publicado: (2023)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome
por: Hinai, Adil S.A. Al, et al.
Publicado: (2019)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

P584: VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL
por: Wang, Huafeng, et al.
Publicado: (2023)

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2022)

Hypothalamic Menin regulates systemic aging and cognitive decline
por: Leng, Lige, et al.
Publicado: (2023)

Development of an orally bioavailable selective inhibitor of the menin-MLL
por: Zhong, Hai-Jing, et al.
Publicado: (2022)

FBP1 Is an Interacting Partner of Menin
por: Zaman, Shadia, et al.
Publicado: (2014)

Menin: Expanding and dichotomous roles in cancer
por: Katona, Bryson W., et al.
Publicado: (2019)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ovqv7ggofhua4mhuv2gkimt38n